**Background:** Accurately diagnosing the etiologic agents of lower respiratory tract infections (LRTI) requires screening for multiple pathogens including bacteria, viruses, and fungi in complex sample types like sputum, endotracheal aspirates (ETA) and bronchoalveolar lavage (BAL). Many potential LRTI pathogens are opportunistic bacteria and actionable diagnosis requires determining clinically significant levels of these organisms. Co-infections can also add to the diagnostic challenge of pneumonia. To address this unmet need in LRTI diagnostics, BioFire Diagnostics, LLC is developing the FilmArray^®^ LRTI Panel; a multiplexed PCR-based test for use on the FilmArray platform. This system will provide a comprehensive result, including bacteria, viruses and fungi, in approximately 1 h. In this study, a research use only prototype of the FilmArray LRTI panel was used to identify the prevalence of adenovirus, coronavirus, human metapneumovirus, influenza A, influenza B, parainfluenza virus, and respiratory syncytial virus in two sample matrices: sputum-like (sputum and ETA) and BAL-like (BAL, mini-BAL, and bronchial wash). The prevalence of viral detections as well as the incidence of co-detections with bacteria and fungi were assessed for both sample types.

**Methods:** This study was conducted using residual fresh sputa, ETA, and BAL that were submitted for standard care testing. Specimens were collected at the Medical College of Wisconsin during November 2014--May 2015. All specimens were tested on the prototype FilmArray LRTI panel. A subset of specimens found to be positive for viruses were verified by another molecular method when a physician specified request for a viral test was not submitted to the laboratory. To date, 156 sputum and 130 BAL-like specimens were tested by FilmArray for this study.

**Results:** Physician requested Nucleic Acid Amplification Tests (NAAT) were only requested in 3.5% (10/286) of all specimens. Of these, all but one NAAT returned negative results. FilmArray confirmed these findings and identified additional viruses in in 18.6% (29/156) of sputum-like and 17% (22/130) of BAL-like specimens. Results from a subset of these viral positive specimens were confirmed by additional PCR assays. Additionally, 62% (18/29) of sputa specimens and 63.6% (14/22) of BAL specimens positive for virus were found to have a co-detection with a bacteria or fungus.

**Conclusions:** The FilmArray can accurately and efficiently detect viral pathogens in lower respiratory sample matrices. These findings highlight the advantages of the multi-target approach offered by the FilmArray LRTI panel where standard of care testing might fail to accurately report incidence of viral pneumonia.
